The Expression of The P53 Gene Suppressor in Breast Cancer

Authors

  • B. B. Latipov Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Bukhara Regional Branch
  • D. A. Nishanov Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, MH RUz
  • M. A. Gafur Akhunov Department of Oncology of the Center for the Development of Professional Qualifications of Medical Workers
  • G. N. Saidov Department of Oncology of the Center for the Development of Professional Qualifications of Medical Workers
  • M. T. Tukhtabayeva Department of Oncology of the Center for the Development of Professional Qualifications of Medical Workers
  • A. B. Yigitaliev Fergana Medical Institute of Public Health

Keywords:

Breast cancer, immunohistochemistry, gene suppressor, tumor Luminal type, prognosis, treatment tactics.

Abstract

The article examines the indicators of the P53 gene suppressor in the Luminal type of breast cancer, and it has been established that the activity of tumor cells depends on the Luminal type. According to the results of the conducted study, the P53 index in Luminal A type of breast cancer had a high positive response in 10% of patients, while in Luminal B type (Her-2 negative), a high positive response was observed in 20% of patients. For luminol B (Her-2-positive), this indicator was 40%. In the basal-like (tripple negative) type, the high positive reaction of P53 was 60%. The Her-2 positive (non-luminal) type also showed a high positive response of 90%. As can be seen from the presented data, a high expression of the p53 gene suppressor is observed in luminal breast tumors, which are prognostically unfavourable. This, of course, should be taken into consideration when determining treatment tactics and studying the prognosis of breast cancer.

References

Бош А.JI., Фос С.Н. Изучение СМТ: от иммуногистохимии до молекулярной биологии. Практический подход // Саркомы костей, мягких тканей и опухоли кожи. - 2010. -Nº1. - С. 24-30.

Кешта Р.А. Молекулярно-биологические маркеры как факторы прогноза при саркомах мягких тканей: Автореф. дис. ... канд. мед.наук. -M., 2002. - 27 с.

Каприн А.Д. Состояние онкологической помощи населению России в 2019 году/Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦрадиологии» Минздрава России, 2020. - илл. - 239 с.

Колесник А.Ю. Молекулярно-биологические свойства отечно-инфильтративной формы рака молочной железы / А.Ю. Колесник и др. // Вопросы онкологии. - 2016. - Т. 62, Nº4. - С.485-489.

Рахимова М.Н., Уразаева С.Т., Уразаев О.Н.,егалин Т.Б. Эпидемиология рака молочной железы в странах СНГ и Республике Казахстан (литературный обзор). West Kazakhstan Medical journal 2019;61(1):46-55.

TNM: Классификация злокачественных опухолей / Под ред. Дж.Д. Брайерли и др.; пер. с англ. и научн. ред. Е.А. Дубовой, К.А. Павлова. 2-еизд. на русском языке. - М.:

Логосфера, 2018. —344 с. Перевод изд. TNM Classification of Malignant Tumours, 8th ed.

Федоров В.Э., Ласкано М., Чебуркаева М.Ю. Характеристика распространения рака молочной железы зарубежом (обзор литературы) / Международный научно исследовательский журнал • Nº4 (46) • Часть 5 •Апрель. С. 138-141. DOI:

Mayer, I. A., et al. (2016). Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nature Reviews Clinical Oncology, 13(5), 335-346.

Jones, M., Brown, K., & Davis, L. (2019). "Stromal cell changes in diffuse breast cancer." Cancer Research, 27(4), 145-156.

А.Р.Бейсенова Роль Иммуногискохимическое исследования в онкологии. Журнал Медицина и экология 2015 г.Nº2 стр.12-16.

Downloads

Published

2024-11-30

How to Cite

B. B. Latipov, D. A. Nishanov, M. A. Gafur Akhunov, G. N. Saidov, M. T. Tukhtabayeva, & A. B. Yigitaliev. (2024). The Expression of The P53 Gene Suppressor in Breast Cancer. International Journal of Scientific Trends, 3(11), 77–86. Retrieved from https://scientifictrends.org/index.php/ijst/article/view/332

Issue

Section

Articles